Action needed to tackle antimicrobial resistance, says IFPMA report

30 April 2015

A global coordinated policy approach to minimize the growth of antimicrobial resistance (AMR) is being called for by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in a new report.

The report highlights the scientific challenges associated with the development of new antibiotics and the need for economic incentives to ensure sustainable investments in antibacterial research and development. AMR is now seen as one of the most pressing health threats the world faces and it is estimated that a continued rise in resistance by 2050 would lead to 10 million people dying every year.

IFPIA analyzed major scientific and economic roadblocks on the way to develop new antibiotics and provided recommendations for new mechanisms to incentivize innovation, meet preservation goals, and ensure access to antibiotics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK